B2M and Alzheimer disease: The dysregulation of key immune mediators, such as pro-inflammatory cytokines, apolipoprotein E4 (APOE4), β2 microglobulin (B2M), and the microglial receptor TREM2, further complicates the neuroimmune landscape, influencing AD progression [9, 10].